Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

The Changing Landscape of Glaucoma Therapies – Part 2

By: Nathan M. Radcliffe, MD (Program Chair); Preeya K. Gupta, MD; Jeffrey M. Liebmann, MD; Felipe Medeiros, MD, PhD

Webinar Credits: 1.5

This webinar will focus on caring for patients with glaucoma and will highlight the ways in which sustained-release therapies can help extend the follow-up interval. In the age of a pandemic, the benefits of longer lasting treatments that increase patient compliance with fewer patients visits have never been more important. This webinar presents the same didactic material as part one, plus new case studies and a recorded question-and-answer session.

Target Audience
This activity will reach glaucoma specialists, general ophthalmologists, and other eye care professionals.

Expiration Date: Wednesday, June 30, 2021
Release Date: June 2020

Learning Objectives

At the completion of this educational activity, you will be better able to:

  • Categorize all available treatment regimens for mild-to-moderate primary open-angle glaucoma (POAG).
  • Identify the effect that traditional topical glaucoma medications have on the ocular surface.
  • Describe ways to overcome issues with patient compliance and adherence.
  • Evaluate novel drug devices for the treatment of POAG as part of individualized therapy.
  • Compare the efficacy of novel therapeutics with traditional prostaglandins.

 

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

 

Course Viewing Requirements

Supported Browsers:

Internet Explorer 11 for Windows

Edge (recent versions; Chromium-based) for Windows

Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:

4GB+ RAM

Recommended internet speed 5Mbps+

 

Faculty and Disclosures

Faculty:

Preeya K. Gupta, MD

Clinical Medical Director
Associate Professor of Ophthalmology
Cornea & Refractive Surgery
Duke University Eye Center
Durham, North Carolina

Jeffrey M. Liebmann, MD

Shirlee and Bernard Brown Professor of Ophthalmology
Director, Glaucoma Service
Vice-chair, Department of Ophthalmology
Columbia University Medical Center
New York, New York

Felipe Medeiros, MD, PhD

Professor of Ophthalmology and Vice Chair of Technology
Duke University
Durham, North Carolina

Nathan M. Radcliffe, MD

Assistant Professor of Ophthalmology
New York Eye Surgery Center
New York Eye and Ear Infirmary of Mount Sinai
New York, New York

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Nathan M. Radcliffe, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Aerie PhnTrarmaceuticals, Alcon, Alimera Sciences, Allergan, Bausch + Lomb, Carl Zeiss Meditec, CATS, Ellex, Endo Optiks, Equinox, Glaukos, Iridex, Ivantis, Lumenis, New World Medical, Novartis, Ocular Science, Omeros, Reichert Technologies, Shire, and Sight Sciences.

Preeya K. Gupta, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Aurea, Carl Zeiss Meditec, Johnson & Johnson Vision, Kala, New World Medical, NovaBay Pharmaceuticals, Novartis, Ocular Science, ReGenTree, Shire, Sight Sciences, Sun Pharmaceuticals, and TearLab.

Jeffrey Liebman, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Novartis, and Thea. Grant/Research Support: Carl Zeiss Meditec, and Topcon. Stock/Shareholder: Qura, and Sustained Nano Systems.

Felipe Medeiros, MD, PhD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Biogen, Galimmedix, Novartis, and Stealth Biotherapeutics. Grant/Research Support: Carl Zeiss Meditec, Google, Inc., and Heidelberg Engineering. Stock/Shareholder: Google, Inc.

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Allergan.

Pretest

  • 1. Not at all confident2. Not very confident3. Neutral4. Confident5. Extremely confident

Video Resources

Next

Test

Instructions

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Step 1 of 2

  • 1. Not at all confident2. Not very confident3. Neutral4. Confident5. Extremely confident
  • AgreeNeutralDisagree
    Categorize all available treatment regimens for mild-to-moderate primary open-angle glaucoma (POAG)
    Identify the effect that traditional topical glaucoma medications have on the ocular surface
    Describe ways to overcome issues with patient compliance and adherence
    Evaluate novel drug devices for the treatment of primary open-angle glaucoma as part of individualized therapy
    Compare the efficacy of novel therapeutics with traditional prostaglandins
Back